Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

LH-001 vs Placebo in Healthy Participants

NCT06546449
View directory record Official record
Conditions
Healthy
Interventions
LH-001, Placebo
Drug
Lead sponsor
Chien-Liang Lin
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery

NCT00894647
View directory record Official record
Conditions
Actinic Keratosis
Interventions
imiquimod cream, placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • Saint Petersberg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 24, 2026, 2:31 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4302814 in Healthy Participants

NCT07566338
View directory record Official record
Conditions
Healthy
Interventions
LY4302814, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

NCT00615433
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 2 Interventional

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

NCT04295538
View directory record Official record
Conditions
Spinal Cord Injury (SCI)
Interventions
Elezanumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 24, 2026, 2:31 PM EDT
Terminated Phase 3 Interventional Results available

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

NCT01764997
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder

NCT02909959
View directory record Official record
Conditions
Autism Spectrum Disorder, Autistic Disorder, Neurodevelopmental Disorder, Childhood Developmental Disorders, Pervasive
Interventions
Sulforaphane, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years to 30 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

NCT05558410
View directory record Official record
Conditions
Acute Pain
Interventions
Suzetrigine (SUZ), HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

NCT00532610
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

NCT05518123
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
962 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Sherman Oaks, California • Stamford, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 2:31 PM EDT
Active, not recruiting Not applicable Interventional

Episealer® Knee System IDE Clinical Study

NCT04000659
View directory record Official record
Conditions
Degenerative Lesion of Articular Cartilage of Knee
Interventions
Episealer Knee System, Microfracture
Device · Procedure
Lead sponsor
Episurf Medical Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
8
States / cities
Tempe, Arizona • La Mesa, California • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

NCT00316459
View directory record Official record
Conditions
Healthy, Long QT Syndrome
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2007 · Synced Oct 24, 2026, 2:31 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

NCT06079359
View directory record Official record
Conditions
Hypophosphatasia
Interventions
ALXN1850, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Baltimore, Maryland • Kansas City, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 24, 2026, 2:31 PM EDT
Terminated Phase 2 Interventional

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01579279
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-652 6 mg, ABT-652 12 mg, ABT-652 12 mg - 18 mg, Placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Anaheim, California • Walnut Creek, California • Milford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 2 Interventional

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

NCT00877903
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Prochymal®, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
32
States / cities
Gilbert, Arizona • Tucson, Arizona • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 24, 2026, 2:31 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

NCT02107703
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Abemaciclib, Fulvestrant, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
43
States / cities
Jonesboro, Arkansas • Springdale, Arkansas • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate and Compare the Rate of Para-Stomal Herniation After Permanent Stoma Formation

NCT00577603
View directory record Official record
Conditions
Hernia
Interventions
mesh reinforcement of stoma, no intervention
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 3 Interventional

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

NCT00158990
View directory record Official record
Conditions
Major Depression, Bipolar Disorder, Unipolar Depression
Interventions
triiodothyronine, sertraline
Drug
Lead sponsor
Hadassah Medical Organization
Other
Eligibility
18 Years to 70 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2007 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

NCT03689010
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid foam 15%, Finacea® (Azelaic acid Foam) 15%, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 1 Interventional

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

NCT00628420
View directory record Official record
Conditions
Schizophrenia
Interventions
ACP-104, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 24, 2026, 2:31 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cidofovir in Renal Transplant Recipients With BKVN

NCT00138424
View directory record Official record
Conditions
BK Virus (Nephropathy)
Interventions
Cidofovir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate a Probiotic in Healthy Subjects With a History of Abdominal Discomfort and Bloating

NCT01099696
View directory record Official record
Conditions
Abdominal Discomfort, Bloating
Interventions
B. infantis 35624, placebo
Dietary Supplement
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
10
States / cities
Chicago, Illinois • Rockford, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 24, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 24, 2026, 2:31 PM EDT